-$0.14 EPS Expected for Kadmon Holdings Inc (NYSE:KDMN) This Quarter

Equities analysts expect Kadmon Holdings Inc (NYSE:KDMN) to report ($0.14) earnings per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Kadmon’s earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.17). Kadmon reported earnings of ($0.19) per share in the same quarter last year, which indicates a positive year over year growth rate of 26.3%. The firm is expected to announce its next earnings report on Monday, August 3rd.

On average, analysts expect that Kadmon will report full year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.63) to ($0.58). For the next year, analysts expect that the company will report earnings of $0.34 per share, with EPS estimates ranging from ($0.62) to $2.97. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that cover Kadmon.

Kadmon (NYSE:KDMN) last announced its earnings results on Thursday, May 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Kadmon had a negative net margin of 813.33% and a negative return on equity of 142.79%. The business had revenue of $6.74 million for the quarter, compared to analysts’ expectations of $0.38 million.

A number of brokerages recently commented on KDMN. Oppenheimer reissued a “buy” rating and issued a $8.00 price objective on shares of Kadmon in a research note on Thursday, May 7th. ValuEngine raised shares of Kadmon from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Kadmon in a research note on Sunday. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Thursday, June 4th. Finally, Raymond James assumed coverage on shares of Kadmon in a report on Tuesday, May 19th. They set an “outperform” rating and a $7.00 price objective on the stock. Seven analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average price target of $10.88.

Several hedge funds and other institutional investors have recently made changes to their positions in KDMN. Fisher Asset Management LLC purchased a new position in shares of Kadmon during the 1st quarter worth approximately $53,000. Windsor Creek Advisors LLC purchased a new position in Kadmon in the 1st quarter valued at approximately $60,000. JS Capital Management LLC purchased a new position in Kadmon in the 1st quarter valued at approximately $65,000. Meeder Asset Management Inc. boosted its position in Kadmon by 49.1% in the 4th quarter. Meeder Asset Management Inc. now owns 14,843 shares of the company’s stock valued at $68,000 after buying an additional 4,888 shares during the period. Finally, Raymond James & Associates purchased a new position in Kadmon in the 1st quarter valued at approximately $73,000. Institutional investors and hedge funds own 85.64% of the company’s stock.

Shares of NYSE KDMN traded down $0.04 during trading hours on Wednesday, reaching $5.14. The stock had a trading volume of 79,709 shares, compared to its average volume of 2,662,520. The company has a current ratio of 6.42, a quick ratio of 6.40 and a debt-to-equity ratio of 0.20. The firm has a market cap of $844.96 million, a price-to-earnings ratio of -7.37 and a beta of 1.47. The business’s fifty day moving average price is $4.58 and its two-hundred day moving average price is $4.42. Kadmon has a 52-week low of $1.82 and a 52-week high of $5.50.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Further Reading: Recession

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kadmon (NYSE:KDMN)

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.